Cambrex has opened a new 20,000 sq ft cGMP facility in Belgium, expanding its capacity for environmentally-controlled stability storage services to the pharmaceutical, medical device and life sciences industries across Europe.

In June 2022, Cambrex announced the acquisition of Q1 Scientific - a leading provider of environmentally-controlled cGMP stability storage services for the pharmaceutical, medical device and life science industries.

Strategically located in the Liege region and approximately 90 kilometers from Brussels, the new state-of-the-art temperature-controlled and monitored storage facility provides 35,000 temperature-controlled storage spaces for all key ICH climatic zones, including long-term, intermediate, and accelerated stability trials including 2 - 8°C, 25°C / 60%RH and 40°C / 75%RH.

This expansion into Belgium complements Q1 Scientific's existing footprint in Waterford, Ireland, and is consistent with Cambrex's strategy to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing across North America and Europe.

Tom Loewald, CEO at Cambrex said, "Following our acquisition of Q1 Scientific in June 2022, we have continued to see an increase in demand for stability storage services. This expansion provides easily accessible capacity in continental Europe, as well as flexibility to react quickly and effectively to customers' changing requirements."

Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialty dosage forms such as modified-release, fixed-dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile, and non-sterile ointments.